Patient baseline demographics and disease characteristics
| Double-blind abatacept ∼10 mg/kg | Double-blind abatacept ∼5 mg/kg | Total | |
|---|---|---|---|
| Number of patients treated | 58 | 50 | 108 |
| Age, years, mean (SD) | 50.1 (11.5) | 51.1 (13.4) | 50.6 (12.3) |
| Female | 44 (75.9) | 41 (82.0) | 85 (78.7) |
| White | 49 (84.5) | 46 (92.0) | 95 (88.0) |
| Duration of RA,* mean (SD) | 2.2 (0.4) | 2.4 (0.5) | 2.3 (0.5) |
| TJC, mean (SD) | 1.4 (2.5) | 1.1 (1.5) | 1.3 (2.1) |
| SJC, mean (SD) | 0.7 (1.4) | 0.5 (1.1) | 0.6 (1.2) |
| HAQ-DI, mean (SD) | 0.5 (0.5) | 0.6 (0.6) | 0.6 (0.5) |
| Patient global assessment, mean (SD) | 14.3 (16.8) | 16.3 (12.9) | 15.3 (15.0) |
| DAS28 (CRP), mean (SD) | 2.1 (0.6) | 2.1 (0.6) | 2.1 (0.6) |
| CRP mg/dL, mean (SD) | 0.5 (0.6) | 0.5 (0.5) | 0.5 (0.5) |
Data are n (%), unless otherwise indicated.
*At the start of the sub-study.
CRP, C reactive protein; DAS, disease activity score; HAQ-DI, Health Assessment Questionnaire–Disability Index; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count.